Raymond James Financial’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.06B Buy
1,713,850
+88,195
+5% +$90.1M 0.56% 25
2026
Q1
$1.49B Buy
1,625,655
+135,697
+9% +$138M 0.46% 30
2025
Q4
$1.6B Buy
1,489,958
+109,239
+8% +$104M 0.5% 29
2025
Q3
$1.05B Sell
1,380,719
-111,158
-7% -$82.7M 0.34% 45
2025
Q2
$1.16B Buy
1,491,877
+20,661
+1% +$16.1M 0.4% 34
2025
Q1
$1.22B Sell
1,471,216
-135,846
-8% -$113M 0.46% 35
2024
Q4
$1.24B Buy
+1,607,062
New +$1.33B 0.46% 30

Other funds holding LLY

Raymond James Financial's LLY Position: Q2 2026 in Review

Raymond James Financial increased its Eli Lilly (LLY) stake by 5.4% in Q2 2026, buying an estimated $90.1M and bringing the position to 1,713,850 shares worth $2.06B. The position accounts for 0.56% of the portfolio, ranked #25.

Raymond James Financial first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Raymond James Financial held 1,713,850 shares of Eli Lilly worth $2.06B as of Q2 2026.
  • Raymond James Financial bought 88,195 Eli Lilly shares in Q2 2026, an estimated $90.1M.
  • Eli Lilly made up 0.56% of Raymond James Financial's portfolio in Q2 2026, its #25 holding.
  • Raymond James Financial first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.